logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hongjian Yang

shenzhen institute of advanced technology, cas
H指数:19
被引数:1,161

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial

TQB2440与参比药pertuzumab对比治疗HER2阳性、ER/PgR阴性早期或局部晚期乳腺癌：一项多中心、随机、双盲、平行对照、III期等效性试验

ESMO Open
IF8.3
2025-12-150
OAAI
S. Wang; N. Li; Q. Cheng; Y. Ren; X. Cao; J. Huang; C. Liu; H. Yang; L. Wei; Z. Song; H. Zhao; Q. Zhang
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial

Efbemalenograstim Alfa，一种Fc融合蛋白，长效粒细胞集落刺激因子，用于降低化疗诱导性中性粒细胞减少症风险：一项II期随机、多中心、开放标签试验的结果

Clinical Drug Investigation
IF2.7
2025-10-090
OA
Dongmei Ji; Shufang Wang; Wei Yao; Denny Hou; Xiaoyan Wang; Changsheng Ye; Hongsheng Li; Hongjian Yang; Jilin Yi; Jinsong Lu; Haibo Wang; Xiaohong Xu; Dongyan Cai; Xiaoan Liu; Xi Yan; Jianyun Nie; Shude Cui; Hongchuan Jiang; Junning Cao
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
BMC CANCER
IF3.4
2024-09-131
OAAI
Zhang, Qingyuan; Wang, Zhonghua; Yao, Wei; Wang, Shufang; Zhang, Gaochong; Chen, Jianmin; Hou, Qingsong; Li, Simon; Li, Hongsheng; Ye, Changsheng; Sun, Tao; Yang, Hongjian; Chen, Zhendong; Wang, Zhihong; Liu, Xiaoan; Geng, Cuizhi; Li, Xingrui; Zhang, Jin; Zheng, Hong; Shao, Zhimin
A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)

预测乳腺癌患者新辅助化疗后病理淋巴结阴性的列线图: 一项全国性多中心回顾性队列研究 (CSBrS-012)

FRONTIERS IN ONCOLOGY
IF3.3
2024-05-100
OAAI
Maimaitiaili, Amina; Li, Yijun; Chai, Na; Liu, Zhenzhen; Ling, Rui; Zhao, Yi; Yang, Hongjian; Liu, Yunjiang; Liu, Ke; Zhang, Jianguo; Mao, Dahua; Yu, Zhigang; Liu, Yinhua; Fu, Peifen; Wang, Jiandong; Jiang, Hongchuan; Zhao, Zuowei; Tian, Xingsong; Cao, Zhongwei; Wu, Kejin; Song, Ailin; Jin, Feng; Wu, Puzhao; He, Jianjun; Fan, Zhimin; Zhang, Huimin
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
NATURE COMMUNICATIONS
IF15.7
2024-03-098
OAAI
Huang, Liang; Pang, Da; Yang, Hongjian; Li, Wei; Wang, Shusen; Cui, Shude; Liao, Ning; Wang, Yongsheng; Wang, Chuan; Chang, Yuan-Ching; Wang, Hwei-Chung; Kang, Seok Yun; Seo, Jae Hong; Shen, Kunwei; Laohawiriyakamol, Suphawat; Jiang, Zefei; Wang, Haiyan; Lamour, Francois; Song, Grace; Curran, Michelle; Duan, Chunzhe; Lysbet de Haas, Sanne; Restuccia, Eleonora; Shao, Zhimin
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
BREAST
IF7.9
2024-02-015
OAAI
Guo, Xuhui; Zhang, Jiao; Gong, Xilong; Wang, Jia; Dai, Hao; Jiao, Dechuang; Ling, Rui; Zhao, Yi; Yang, Hongjian; Liu, Yunjiang; Liu, Ke; Zhang, Jianguo; Mao, Dahua; He, Jianjun; Yu, Zhigang; Liu, Yinhua; Fu, Peifen; Wang, Jiandong; Jiang, Hongchuan; Zhao, Zuowei; Tian, Xingsong; Cao, Zhongwei; Wu, Kejin; Song, Ailin; Jin, Feng; Fan, Zhimin; Liu, Zhenzhen
Association of a complete breast cancer pathologic response with axillary lymph node metastasis via neoadjuvant chemotherapy: Results from the CSBrS-012 study
CHINESE MEDICAL JOURNAL
IF7.3
2023-10-250
OAAI
Ma, Le; Gao, Pin; Liu, Zhenzhen; Jiao, Dechuang; Ling, Rui; Xiao, Jingjing; Zhao, Yi; Wang, Yitong; Yang, Hongjian; Liu, Yunjiang; Liu, Ke; Zhang, Jianguo; Li, Guangyan; Mao, Dahua; Deng, Yinglei; He, Jianjun; Amina, Maimaitiaili; Yu, Zhigang; Fei, Wang; Liu, Yinhua; Fu, Peifen; Yao, Minya; Wang, Jiandong; Zhu, Li; Jiang, Hongchuan; Zhao, Zuowei; Tian, Xingsong; Cao, Zhongwei; Ma, Xinyu; Wu, Kejin; Fu, Shaomei; Song, Ailin; Wang, Yanwei; Feng, Jin; Fan, Zhimin
Final analysis of the Phase III PEONY trial: long-term efficacy and safety of neoadjuvant-adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer
CANCER RESEARCH
IF16.6
2023-03-011
PRE
Shao, Zhi-Ming; Pang, Da; Yang, Hongjian; Li, Wei; Wang, Shusen; Cui, Shude; Liao, Ning; Wang, Yong-Sheng; Wang, Chuan; Chang, Yuan-Ching; Wang, Hwei-Chung; Kang, Seok Yun; Seo, Jae Hong; Shen, Kunwei; Laohawiriyakamol, Suphawat; Jiang, Zefei; Huang, Liang; Wang, Haiyan; Lamour, Francois; Song, Grace; Restuccia, Eleonora
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2023-02-282
OAAI
Chen, Heyan; Maimaitiaili, Amina; Liu, Zhenzhen; Ling, Rui; Zhao, Yi; Yang, Hongjian; Liu, Yunjiang; Liu, Ke; Zhang, Jianguo; Mao, Dahua; Yu, Zhigang; Liu, Yinhua; Fu, Peifen; Wang, Jiandong; Jiang, Hongchuan; Zhao, Zuowei; Tian, Xingsong; Cao, Zhongwei; Wu, Kejin; Song, Ailin; Jin, Feng; He, Jianjun; Fan, Zhimin; Zhang, Huimin
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

pyrotinib、曲妥珠单抗和多西他赛新辅助治疗HER2-positive乳腺癌 (PHEDRA): 一项双盲、随机3期试验

BMC MEDICINE
IF8.3
2022-12-2748
OAAI
Wu, Jiong; Jiang, Zefei; Liu, Zhenzhen; Yang, Benlong; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Zhu, Xiaoyu; Wu, Fei; Lin, Xiang; Zou, Jianjun
Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
CANCER RESEARCH
IF16.6
2022-02-150
PRE
He, Min; Yang, Benlong; Wu, Jiong; Liu, Zhenzhen; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Jiang, Zefei; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Zhu, Xiaoyu; Liu, Shulin; Yan, Ping; Zou, Jianjun
Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study
CANCER RESEARCH
IF16.6
2022-02-150
PRE
Wu, Jiong; Liu, Zhenzhen; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Jiang, Zefei; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Zhu, Xiaoyu; Wu, Fei; Zhang, Tao; Zou, Jianjun
Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
CANCER RESEARCH
IF16.6
2022-02-150
PRE
Yang, Benlong; Wu, Jiong; Liu, Zhenzhen; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Jiang, Zefei; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Wu, Fei; Liu, Shulin; Lin, Xiang; Zou, Jianjun

研究方向

暂未获取到该数据
S
Shusen Wang
H 指数:39论文数:237被引数:6,448
于
于洋
H 指数:37论文数:256被引数:5,289
刘真真 封面图
刘真真
H 指数:43论文数:474被引数:6,674
C
Chuan Wang
H 指数:26论文数:200被引数:2,352
Z
Zefei Jiang
H 指数:46论文数:376被引数:1.5万
X
Xingfei Yu
H 指数:13论文数:44被引数:576
Y
Yunjiang Liu
H 指数:20论文数:96被引数:1,665
H
Hongbin Zhai
H 指数:38论文数:213被引数:4,101
J
Jianjun He
H 指数:32论文数:129被引数:3,321
Y
Yongsheng Wang
H 指数:27论文数:172被引数:2,583